Trial Profile
A clinical study of TPST‐1120 in advance Cancer
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 05 Dec 2018
Price :
$35
*
At a glance
- Drugs TPST-1120 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 05 Dec 2018 New trial record
- 13 Nov 2018 According to a Tempest Therapeutics media release, the company expects to start this study in early 2019.